The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•
Capsugel Lonza — A Better Way to Deliver Microbiome-Based Therapies

Latest in the News

All News →
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
 CLINICAL & MANUFACTURING

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

MaaT Pharma proposed conducting a randomized controlled Phase 3 trial versus Best Available Therapy (BAT), named PHOENIX, which would serve the purpose of regulatory submission in the U.S., Europe and other territories

BY Microbiome Times · SEP 18, 2026 · 5 MIN READ
Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
FINANCE

Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health

SEP 16, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
INFECTIOUS DISEASE & AMR

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

SEP 15, 2026
GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions
CLINICAL & MANUFACTURING

GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions

SEP 11, 2026
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics
CLINICAL & MANUFACTURING

From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics

SEP 4, 2026
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
EDITOR'S CHOICE

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
Evonik EUDRACAP colon - GMP quality targeted drug delivery from the upper small intestine to the ileo-colonic region

Editor's Choice

All Editor's Choice →
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
 Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

Caelus welcomes the publication by the European Food Safety Authority (EFSA) of its scientific opinion on the safety of gut bacterium Anaerobutyricum soehngenii CH106 (A. soehngenii) for use in food

BY Microbiome Times · SEP 1, 2026 · 3 MIN READ
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026
LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
Editor's Choice

LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis

MAY 1, 2026